Anthraquinone compounds useful to treat osteoarticular condition

Details Anthraquinone compounds useful to treat osteoarticular condition Anthraquinone compounds useful to treat osteoarticular condition

1993-10-06

1995-09-19

Cook, Rebecca

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

552262, C07C23566, A61K 31195

Patent

active

054516064

DESCRIPTION:

BRIEF SUMMARY
This application is a 371 of PCT/EP 92/00479 filed Mar. 4, 1992.
The present invention relates to compounds of general formula (I) ##STR3## wherein: X is selected from H and OH; ##STR4## group, forms an amino acid; the enantiomers and racemic mixtures thereof; and the pharmaceutically acceptable salts thereof. Particularly preferred are those compounds in which R is a residue which, linked to the ##STR5## group, forms a natural amino acid.
The compounds of the invention derive from rhein, which has some therapeutical properties; particularly known is the antiarthritic activity of diacerhein, which is the rhein diacetyl derivative.
The derivatives of rhein with natural amino acids, which are the object of the present invention, proved to have interesting pharmacological activities which make them useful for the treatment of articular pathologies. In fact, preliminary pharmacological research evidenced a marked inhibiting action on the elastase activity of human leukocytes, as well as an inhibiting activity on free radical formation.
The compounds of the invention are prepared according to conventional methods. Condensation of diacetylrhein with a compound of formula ##STR6## wherein R.sup.1 is a C.sub.1 -C.sub.4 alkyl group, is carried out in anhydrous solvents such as methylene chloride, and in the presence of acid-binding agents, for example triethylamine. The 4,5-hydroxy groups, and optionally the 8-hydroxy group, on the aromatic ring, and the carboxy group on the amino acidic portion are restored by means of hydrolysis of the corresponding esters. An embodiment of the invention comprises the use of diacetylrhein chloride.
The following examples further illustrate the invention.


EXAMPLE



2-[[4,5-Dihydroxy-9,10-dihydro-9,10-dioxo-2-anthracene-yl]carbonyl]amino-4-
methyl-pentanoic acid.
3.1 g (8 mmoles) of 4,5-dihydroxy-9,10-dihydro-9,10-dioxo-2-anthracenecarboxylic acid chloride are added under stirring to a solution of dichloromethane (70 ml) containing 1.8 g (10 mmoles) of methyl 2-amino-4-methyl-pentanoate hydrochloride, 50 mg of p-N,N-dimethylamino-pyridine and 2.4 ml (16 mmoles) of triethylamine. The mixture is refluxed for 5 minutes, then it is left under stirring at room temperature for a night.
The reaction is controlled by means of thin layer chromatography on silica gel plates, using as eluent dichloromethane-diethyl ether in a 10:1 ratio.
At the end of reaction, the reaction mixture is washed with water, the organic phase is separated and solvent is evaporated off under reduced pressure and the residue is taken up into 50 ml of methanol and a solution of 5 g of potassium hydroxide in 50 ml of water, to obtain a purple solution. After about 30 minutes, the solution is acidified with 8% hydrochloric acid and filtered.
The precipitate is crystallized from an acetone-diethyl ether mixture, to obtain about 1,4 g of a product with


______________________________________ Elementary analysis for C.sub.21 H.sub.19 NO.sub.7 calculated % found % ______________________________________ C 63.47 63.40 H 4.81 4.77 N 3.52 3.56 ______________________________________
Analogously, the following compounds were prepared:


______________________________________ Ex. N R Formula M.p. ______________________________________ 2 (CH.sub.3).sub.2 CH-- C.sub.20 H.sub.17 NO.sub.7 >210.degree. C. 3 CH.sub.3 S(CH.sub.2).sub.2 -- C.sub.20 H.sub.17 NO.sub.7 S ______________________________________
The elementary analysis and the IR and .sup.1 H-NMR spectra are in agreement with the formulae and structures.
The compounds of the invention, due to the above mentioned pharmacological properties thereof, can be used as active ingredients in pharmaceutical forms prepared according to known techniques.
Examples of pharmaceutical forms are tablets, capsules, powders, syrups, injectable forms, suppositories.
The dosage unit will range from 5 to 500 mg of active ingredient per dose. The posology will depend on the severity of the disease to treat and the patient's conditions.
1. A compound of formul

REFERENCES:
patent: 4966918 (1990-10-01), Watanabe et al.

Affiliated with

Also associated with

Rating

Anthraquinone compounds useful to treat osteoarticular condition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anthraquinone compounds useful to treat osteoarticular condition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anthraquinone compounds useful to treat osteoarticular condition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1828486